Helixmith Co., Ltd (084990.KQ)
KRW 2770.0
(0.0%)
KRW 2770.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -53 Billion KRW | 41.73% |
| 2022 | -30.48 Billion KRW | -6.34% |
| 2021 | -52.99 Billion KRW | 8.28% |
| 2020 | -41.29 Billion KRW | -10.86% |
| 2019 | -99.51 Billion KRW | -100.68% |
| 2018 | -27.66 Billion KRW | -191.79% |
| 2017 | -5.95 Billion KRW | -320.71% |
| 2016 | -1.58 Billion KRW | -196.16% |
| 2015 | 856.3 Million KRW | 0.0% |
| 2013 | 949.22 Million KRW | 210.02% |
| 2012 | -3.45 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -4.64 Billion KRW | 87.34% |
| 2024 Q2 | -4.82 Billion KRW | 23.81% |
| 2023 Q4 | -3.51 Billion KRW | 32.5% |
| 2023 FY | - KRW | 41.73% |
| 2023 Q1 | -9.4 Billion KRW | 23.05% |
| 2023 Q2 | -6.41 Billion KRW | 31.78% |
| 2023 Q3 | -5.21 Billion KRW | 18.81% |
| 2022 FY | - KRW | -6.34% |
| 2022 Q2 | -10.41 Billion KRW | -14.8% |
| 2022 Q3 | -9.61 Billion KRW | 7.68% |
| 2022 Q1 | -9.07 Billion KRW | 24.98% |
| 2022 Q4 | -12.22 Billion KRW | -27.14% |
| 2021 Q3 | -9.45 Billion KRW | -12.57% |
| 2021 Q4 | -12.09 Billion KRW | -27.89% |
| 2021 FY | - KRW | 8.28% |
| 2021 Q2 | -8.4 Billion KRW | 13.47% |
| 2021 Q1 | -9.7 Billion KRW | -1644.26% |
| 2020 FY | - KRW | -10.86% |
| 2020 Q1 | -8.32 Billion KRW | 1.32% |
| 2020 Q2 | -24 Billion KRW | -188.49% |
| 2020 Q3 | -11.29 Billion KRW | 52.96% |
| 2020 Q4 | 628.6 Million KRW | 105.57% |
| 2019 Q2 | -9.49 Billion KRW | -22.58% |
| 2019 FY | - KRW | -100.68% |
| 2019 Q1 | -7.74 Billion KRW | -2.37% |
| 2019 Q4 | -8.43 Billion KRW | 21.06% |
| 2019 Q3 | -10.68 Billion KRW | -12.49% |
| 2018 FY | - KRW | -191.79% |
| 2018 Q3 | -5.53 Billion KRW | -52.76% |
| 2018 Q4 | -7.56 Billion KRW | -36.71% |
| 2018 Q2 | -3.62 Billion KRW | -53.18% |
| 2018 Q1 | -2.36 Billion KRW | -43.23% |
| 2017 Q3 | -1.74 Billion KRW | -4.87% |
| 2017 FY | - KRW | -320.71% |
| 2017 Q2 | -1.66 Billion KRW | -4.57% |
| 2017 Q1 | -1.59 Billion KRW | 0.0% |
| 2017 Q4 | -1.65 Billion KRW | 5.41% |
| 2016 FY | - KRW | -196.16% |
| 2015 FY | - KRW | 0.0% |
| 2014 Q1 | -719.73 Million KRW | -164.9% |
| 2014 Q3 | -338.03 Million KRW | -401.93% |
| 2014 Q2 | -67.34 Million KRW | 90.64% |
| 2013 FY | - KRW | 210.02% |
| 2013 Q3 | 167.29 Million KRW | 1253.18% |
| 2013 Q2 | -14.5 Million KRW | 95.36% |
| 2013 Q1 | -312.61 Million KRW | 57.65% |
| 2013 Q4 | 1.1 Billion KRW | 562.95% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q4 | -738.13 Million KRW | -201.77% |
| 2012 Q3 | 725.29 Million KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Co., Ltd. | -172.27 Billion KRW | 69.234% |
| iNtRON Biotechnology, Inc. | -6.23 Billion KRW | -750.152% |
| BINEX Co., Ltd. | 10.87 Billion KRW | 587.526% |
| Bioneer Corporation | 10.04 Billion KRW | 627.76% |
| Anterogen.Co.,Ltd. | -437.82 Million KRW | -12006.239% |
| MEDIPOST Co., Ltd. | -19.39 Billion KRW | -173.334% |
| CrystalGenomics, Inc. | -42.79 Billion KRW | -23.849% |
| Chabiotech Co.,Ltd. | 70.08 Billion KRW | 175.625% |
| Medy-Tox Inc. | 32.69 Billion KRW | 262.101% |
| Peptron, Inc. | -12.65 Billion KRW | -318.988% |
| Amicogen, Inc. | 13.95 Billion KRW | 479.872% |
| Genexine, Inc. | -40.87 Billion KRW | -29.664% |
| HLB Therapeutics Co.,Ltd. | 8.22 Billion KRW | 744.067% |
| LegoChem Biosciences, Inc. | -71.38 Billion KRW | 25.749% |
| ALTEOGEN Inc. | 440.04 Million KRW | 12145.237% |
| PharmaResearch Co., Ltd. | 104.25 Billion KRW | 150.841% |
| SillaJen, Inc. | -17.35 Billion KRW | -205.456% |
| JETEMA, Co., Ltd. | 11 Billion KRW | 581.516% |
| OliX Pharmaceuticals,Inc | -11.13 Billion KRW | -376.011% |
| Genomictree Inc. | -6.33 Billion KRW | -737.105% |
| MedPacto, Inc. | -32.6 Billion KRW | -62.546% |
| D&D Pharmatech | -9.05 Billion KRW | -485.169% |
| EASY BIO,Inc. | 24.32 Billion KRW | 317.915% |
| GI Innovation, Inc. | -51.33 Billion KRW | -3.26% |